The evolution of oral ibandronate: Preclinical and clinical development of a new once-monthly bisphosphonate - Foreword

被引：0
|
作者：
Papapoulos, SE [1 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2333 ZA Leiden, Netherlands
来源：
BONE | 2006年 / 38卷 / 04期
关键词：
D O I：
10.1016/j.bone.2006.01.154
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [21] Improved patient satisfaction in post-menopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate
    Martens, Mark
    Bonnick, Sydney L.
    Komowski, Anne
    Bachmann, Gloria
    Recker, Robert R.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (06): : 1006 - 1006
  • [22] ONCE-MONTHLY ORAL IBANDRONATE TREATMENT IN AN ADOLESCENT WITH RECURRENT FRACTURES AND INADEQUATELY LOW BONE MASS
    Kutilek, Stepan
    Plasilova, Ivana
    Nemec, Vladimir
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2012, 48 (07) : 622 - 623
  • [23] Response to once-monthly and daily oral ibandronate in the mobile study: 2-year analysis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S145 - S145
  • [24] Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis
    Lewiecki, E. Michael
    Keaveny, Tony M.
    Kopperdahl, David L.
    Genant, Harry K.
    Engelke, Klaus
    Fuerst, Thomas
    Kivitz, Alan
    Davies, Richard Y.
    Fitzpatrick, Lorraine A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (01): : 171 - 180
  • [25] Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: Results of BALTO II
    Hadji, P.
    Benhamou, C. -L.
    Devas, V.
    Masanauskaite, D.
    Barrett-Connor, E.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S69 - S69
  • [26] Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis: The BALTO II study
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S127 - S128
  • [27] The BALTO II study: Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis
    Minne, H.
    Bourgeois, P.
    Devas, V.
    Masanauskaite, D.
    Minic, B.
    Licata, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 423 - 423
  • [28] Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results From the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) Study
    Emkey, Ronald
    Delmas, Pierre D.
    Bolognese, Michael
    Borges, Lindolfo C.
    Cosman, Felicia
    Ragi-Eis, Sergio
    Recknor, Christopher
    Zerbini, Cristiano A.
    Neate, Colin
    Sedarati, Farhad
    Epstein, Solomon
    CLINICAL THERAPEUTICS, 2009, 31 (04) : 751 - 761
  • [29] Patient preference study of once-monthly ibandronate versus once-weekly alendronate
    Emkey, R
    Binkley, N
    Seidman, L
    Rosen, C
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 797 - 797
  • [30] Once-monthly oral ibandronate is at least as effective as daily oral ibandronate in postmenopausal osteoporosis: 2-year findings from MOBILE.
    McClung, MR
    Drezner, MK
    Reginster, JY
    Bolognese, M
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Delmas, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S395 - S395
12345